跳至主要内容
临床试验/ISRCTN01852072
ISRCTN01852072已完成3 期

A randomised controlled trial comparing standard chemotherapy followed by resection versus Epirubicin, Cisplatin and Xeloda (ECX) chemotherapy followed by resection in patients with resectable adenocarcinoma of the oesophagus

Medical Research Council (MRC) (UK)0 个研究点目标入组 897 人开始时间: 2004年8月3日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
897

研究概览

简要总结

2015 Abstract results in https://doi.org/10.1093/annonc/mdv262.03 results 2017 Results article in https://www.ncbi.nlm.nih.gov/pubmed/28784312 results

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Histologically verified adenocarcinoma of the oesophagus or type 1 and type 2 adenocarcinoma of the oesophago-gastric junction
  • 2. Adenocarcinoma as above, which includes disease staged as T1 N1, T2 N1, T3 N0, and T3 N1 as assessed by spiral computed tomography (CT) or endoscopic ultrasound. T4 tumours that involve only the diaphragm or crura as well as T4 tumours invading the mediastinal pleura only.
  • 3. Tumours with nodal disease (N1) affecting the origin of the left gastric and splenic artery with the coeliac axis (hitherto staged as M1a)
  • 4. World Health Organisation (WHO) performance status 0 or 1
  • 5. Proven respiratory cardiac, hepatic, renal and haematological function to the following levels: forced expiratory volume in 1 second (FEV1) >1.5 litres; cardiac ejection fraction >50% of normal echocardiography; liver function tests not more than 1.5 x normal; glomerular filtration rate =60 ml/min; white blood cell count >3 x 10^9/l; platelets >100 x 10^9/l (from the time diagnosis of cancer was first suspected).
  • 6. Written informed consent

排除标准

  • Does not match inclusion criteria

研究者

发起方
Medical Research Council (MRC) (UK)

相似试验